A working meeting was held between the Chairman of the Management Board of SK-Pharmaceuticals LLP, Erken Zhakatay, and representatives of Roche Kazakhstan LLP. At the meeting, the parties discussed the current status and prospects for the implementation of an investment project to localize the production of innovative medicines intended for the treatment of breast cancer.
General Director for Kazakhstan at Roche, Senel Toilan, said that as part of the project to localize production, antitumor drugs passed state registration in Kazakhstan and received the appropriate permits.
He also added that documents are currently being prepared to obtain the ST-KZ certificate for localized products. In addition, the transfer of technologies and production continues. The first commercial products are expected to be delivered this year.
It should be noted that the “ST-KZ” certificate is one of the documents confirming the production of goods in Kazakhstan, and representing preferences from the state in the form of a 10-year offtake contract for the supply of medicines and medical products within the framework of the State Fund for Medical Care and Compulsory Medical Insurance.
At the end of the meeting, representatives of Roche Kazakhstan expressed confidence that the companies will continue to develop interaction within the framework of the investment project, as well as strengthen bilateral cooperation on current issues in the development of the healthcare system.
It is worth recalling that on November 17, 2023, a long-term agreement was signed between SK-Pharmacia LLP and the Swiss pharmaceutical company Roche Holding AG for the production in the Republic of Kazakhstan of four original drugs: Perjeta 420 mg/14 ml, Herceptin 600 mg/ml , Kadcyla 100 mg and 160 mg. They are intended for the treatment of oncological diseases, namely breast cancer, based on the domestic manufacturer Nobel AFF JSC.
.png)
.png)
.jpeg)